# Psychiatry Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Vincent van Gogh (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI010-SYN-TD
- Date: 1889-02-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Jonah Feld, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Elise Verhoeven, MD

## Reason for consultation

First episode of psychosis with mood features in a 35-year-old painter, twelve days after discharge from a first psychiatric admission. He takes aripiprazole 10 mg daily, started in hospital, and drinks heavily. Please review the provisional diagnosis and differential, the medication plan, the treatment of his alcohol use, and the workup for seizures, and enroll him in coordinated specialty care. **S**

## History

Mr. van Gogh, a 35-year-old painter, is seen at the request of Dr. Verhoeven four weeks after aripiprazole 10 mg was started in hospital. He has taken every dose. The confusion of the acute episode has cleared, and he hears nothing by day, but on some nights he hears his name called as he falls asleep and feels briefly that people in the street are talking about him. In the weeks before the episode he slept three or four hours a night, painted almost continuously, and felt full of energy and plans; he was drinking five or six drinks a day, and the confusion began soon after he stopped drinking abruptly. Since discharge his mood has been low and he feels ashamed of what he cannot remember; passive thoughts that it would be easier not to wake up are becoming less frequent, and he has no intent or plan. He drinks two or three glasses of wine most evenings. He has never had a seizure, lost time, or had spells of odd smells or sudden fear. He had his brain MRI and EEG this morning. He wants to understand what happened and to paint again. **S**

## Examination

| System | Finding |
|---|---|
| General | Well; blood pressure 124/78, pulse 82; waist 86 cm |
| Neurological | No akathisia, rigidity, tremor, or abnormal movements; AIMS score 0 |
| Mental status | Quiet and cooperative; affect constricted but reactive; thought process organized; no hallucinations or delusions elicited; no suicidal intent or plan; insight good |

BP 124/78 mmHg; pulse 82 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 64.5 kg; BMI 22.3 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Verhoeven's intake note, safety assessment, and safety plan. Intake results: MCV 102 fL; AST 58, ALT 44, GGT 96 U/L; PEth 284 ng/mL; creatinine 0.94 mg/dL; fasting glucose 91 mg/dL; A1c 5.3%; total cholesterol 184, LDL 106, HDL 52, triglycerides 130 mg/dL; TSH 1.8 mIU/L; vitamin B12 388 pg/mL; urine drug test negative; HIV and syphilis tests nonreactive. PHQ-9 13 at intake and 11 today; AUDIT-C 9. Weight 64.5 kg today, from 64.0. Brain MRI and EEG done this morning; reports pending. PHQ-9: 11. All results are synthetic.

## Assessment

1. **First episode of psychosis with mood features, provisional diagnosis** (F29). The leading possibilities are bipolar I disorder with psychotic features, suggested by weeks of reduced need for sleep and increased activity before the episode and low mood after it, and a psychosis caused by heavy drinking and its abrupt withdrawal, suggested by the timing; the two may have combined. A brief psychotic or schizophreniform disorder remains possible; schizophrenia is less likely with this course. Focal epilepsy is unlikely without seizure-like events but is reasonable to look for once. The diagnosis should stay provisional and be settled by the course: a later manic or depressive episode would point to bipolar disorder, and psychosis without mood change or alcohol to a schizophrenia-spectrum disorder. Aripiprazole is a sound choice for its low metabolic and prolactin effects; the residual night-time symptoms justify a modest increase. A mood stabilizer is not needed now, because aripiprazole also treats mania; lithium would be the first choice if a mood episode occurs. **S**
2. **Alcohol use disorder, moderate** (F10.20). Drinking is the most changeable risk for relapse and for suicide. He takes no opioids, and his liver tests are well below three times the upper limit, so naltrexone is suitable. **S**
3. **Self-injury during confusion** (Z91.52). The injury happened in confusion and without suicidal intent; his current passive thoughts of not waking up are a separate and treatable part of his low mood. His risk is raised in the months after a first episode, and the safety plan is appropriate. **S**

## Recommendations

1. Increase aripiprazole to 15 mg once daily; if akathisia appears, go back to 10 mg rather than add more medicines, and treat it with propranolol if needed.
2. No mood stabilizer now; consider lithium if a manic or depressive episode occurs.
3. Complete the brain MRI and sleep-deprived EEG; if both are normal and there are no seizure-like events, no further epilepsy testing is needed.
4. Start naltrexone 50 mg daily, continue thiamine, follow drinking with PEth, and treat alcohol and psychosis together in the same team.
5. Enroll him in coordinated specialty care now: care coordination, individual resilience-focused therapy, education for him and the people he chooses, supported return to work, and peer support.
6. Monitor weight at every visit for six months, blood pressure, fasting glucose, A1c and lipids at about 12 weeks and then yearly, akathisia and parkinsonism at each visit early on, and the AIMS every six months.
7. Measure the PHQ-9 at least monthly while he is depressed and review suicide risk at every contact.
8. Treat sleep loss as an early warning sign: regular hours and a plan to call the team after two short nights.
9. Continue the antipsychotic after remission; review the length of treatment with him near the one-year mark, with a written relapse plan before any reduction.

## Strengths and supports

- Supports: a friend he paints with who lives nearby, and the coordinated specialty care team; his work is his strongest reason to get well. He decides who is told about his health **S**

## Communication

Discussed with Dr. Verhoeven, who sees him the same day. The plan was explained to Mr. van Gogh, who agreed with it and chose to start the coordinated specialty care program; he decides who else receives this note. **S**

## Follow-up

Psychiatry review through the coordinated specialty care team as needed, and near the one-year mark about the length of treatment; Dr. Verhoeven continues prescribing and monitoring. **S**

## Guideline basis

- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020), American Psychiatric Association (American Journal of Psychiatry)
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018), CANMAT and ISBD (Bipolar Disorders)
- The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence (2023), Focus (American Psychiatric Publishing)
- Consensus development conference on antipsychotic drugs and obesity and diabetes (2004), American Diabetes Association, American Psychiatric Association, AACE, and NAASO (Diabetes Care)
- Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026), National Institute of Mental Health
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
